This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lapchak, P. A. Articles by Zivin, J. A. Search for Related Content PubMed PubMed Citation Articles by Lapchak, P. A. Articles by Zivin, J. A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Stroke Related Collections Acute Cerebral Hemorrhage Embolic stroke Emergency treatment of Stroke Neuroprotectors Thrombolysis

(Stroke. 2002;33:147.)
© 2002 American Heart Association, Inc.

Original Contributions

The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator–Induced Intracerebral Hemorrhage After Thromboembolic Stroke

Paul A. Lapchak, PhD; Dalia M. Araujo, PhD; Donghuan Song, MD Justin A. Zivin, MD, PhD

From the Department of Neuroscience, University of California at San Diego, La Jolla (P.A.L., D.S., J.A.Z.); Veterans Affairs San Diego Healthcare System (P.A.L., D.M.A., D.S., J.A.Z.); and Veterans Medical Research Foundation (P.A.L., J.A.Z.), San Diego, Calif.

Correspondence to Dr Paul A. Lapchak, Department of Neuroscience, University of California at San Diego, MTF 316, 9500 Gilman Dr, La Jolla, CA 92093-0624. E-mail plapchak{at}ucsd.edu

Background and Purpose— Platelet activation and deposition in brain microvessels appear to be key events in the pathogenesis of ischemia-induced neuronal degeneration and behavioral deficits. It has been hypothesized that activated platelets in combination with polymorphonuclear leukocytes and fibrin may play a role in vessel reocclusion leading to the "no-reflow" phenomenon after administration of the thrombolytic tissue plasminogen activator (tPA). We studied the effects of the novel glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 when administered in combination with tPA on infarct and hemorrhage rate and volume to determine whether activated platelets are involved in either infarct or hemorrhage generation after a thromboembolic stroke.

Methods— One hundred thirty-two male New Zealand White rabbits were included in the present study. Rabbits were embolized by injecting a blood clot into the middle cerebral artery via a catheter. Five or 65 minutes after embolization, SM-20302 (5 mg/kg) was infused intravenously. In drug combination studies, tPA was infused intravenously for 30 minutes starting 60 minutes after embolization, and SM-20302 was administered 5 or 65 minutes after embolization. Postmortem analysis included assessment of hemorrhage, infarct size and location, and clot lysis.

Results— In the vehicle control group, the hemorrhage rate after a thromboembolic stroke was 33%. There was a significant increase (109%) in the hemorrhage rate in the group of rabbits treated with the thrombolytic tPA. SM-20302 by itself did not significantly alter the embolism-induced hemorrhage rate when administered either 5 or 65 minutes after embolism. The SM-20302 groups had a 42% and 33% incidence of hemorrhage in the 5- and 65-minute groups, respectively. In groups treated with a combination of drugs, the SM-20302/tPA group had a 31% and 71% incidence of hemorrhage when SM-20302 was administered 5 and 65 minutes after embolization, respectively. SM-20302 in combination with tPA also significantly increased infarct rate, but not hemorrhage or infarct volume.

Conclusions— This study suggests that treatment of thromboembolic stroke with the combination of a platelet inhibitor and tPA may have a beneficial outcome on the basis of the following: First, acute administration of SM-20302 did not significantly increase hemorrhage rate. Second, SM-20302 in combination with tPA significantly reduced tPA-induced intracerebral hemorrhage. Third, there appears to be a specific window of opportunity when a platelet inhibitor must be administered to produce a beneficial effect. Overall, on the basis of our results, we hypothesize that the increased rate of intracerebral hemorrhage observed after tPA administration may be partly due to increased reocclusion of cerebral vessels following lysis of the emboli and that reocclusion can be controlled by administration of a platelet inhibitor.

Key Words: ischemia • neuroprotection • platelet aggregation • reperfusion injury • tissue plasminogen activator • vascular diseases • rabbits

This article has been cited by other articles:

				P. A. Lapchak, M.-K. Han, K. F. Salgado, J. Streeter, and J. A. Zivin Safety Profile of Transcranial Near-Infrared Laser Therapy Administered in Combination With Thrombolytic Therapy to Embolized Rabbits Stroke, November 1, 2008; 39(11): 3073 - 3078. [Abstract] [Full Text] [PDF]

				R. Jahan, D. Stewart, H. V. Vinters, W. Yong, F. Vinuela, P. Vandeberg, and V. J. Marder Middle Cerebral Artery Occlusion in the Rabbit Using Selective Angiography: Application for Assessment of Thrombolysis Stroke, May 1, 2008; 39(5): 1613 - 1615. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, D. M. Araujo, S. Pakola, D. Song, J. Wei, and J. A. Zivin Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits Stroke, September 1, 2002; 33(9): 2279 - 2284. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, D. M. Araujo, D. Song, J. Wei, R. Purdy, and J. A. Zivin Effects of the Spin Trap Agent Disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) on Intracerebral Hemorrhage in a Rabbit Large Clot Embolic Stroke Model: Combination Studies With Tissue Plasminogen Activator Stroke, June 1, 2002; 33(6): 1665 - 1670. [Abstract] [Full Text] [PDF]